Study of the comparative effects of fluoxetine and ziprasidone in albino rats by using tail suspension test model

Hansraj Kumar, Akash Chandra, Uma Shankar Prasad Keshari, Rajiv Kumar


Background: Depression is a group of disorders results from a combination of multiple etiologic factors- genetic, biochemical, psychodynamic and socio-environmental. A depression consists of following clinical features as sadness, apathy, changes in sleep pattern, impaired concentration, feeling of shame or guilt and thoughts of dying or death. Fluoxetine and Ziprasidone both are used for the treatment of Depression in human being. Fluoxetine is Selective serotonin reuptake inhibitors (SSRI) and Ziprasidone is atypical antipsychotic.

Methods: Healthy male albino rats weighing between 150-200 grams were taken for the present study. Study animals were divided into three groups randomly with each group consisting of ten animals. Drugs were powdered with help of mortar and pestle and mixed in gum acacia solution. Appropriate volume of the freshly prepared solution was administered orally daily between 9 am to 10 am to all animal as per their individual body weight. Group A administered 1ml of 0.9% normal saline orally and serves as control group. Group B administered 0.4 mg of fluoxetine orally. Group C administered 1.6 mg of ziprasidone orally. Animals were evaluated for antidepressant activity using two models – Tail suspension test and Forced swimming test.

Results: The results in the tail suspension test were assessed by duration of immobility in 6 minutes duration. Antidepressant activity is indicated by the reduction in the duration of immobility i.e. lesser the duration indicates more effectiveness of the drug.

Conclusions: There is significant difference in antidepressant activity of fluoxetine with antidepressant

 activity of ziprasidone.  


Psychodynamic, SSRI, Tail suspension test, Forced swimming test

Full Text:



Gupta SK. Drug Screening methods, 3rd edition. 2015;27:404.

Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL et al. (eds.) Harrison’s principals of internal medicine Vol 2 19th ed. New York: McGraw Hill. 2015;2714-717.

Suominen KH, Isometsa ET, Henriksson MM, Ostamo AI, Lonnqvist JK. Inadequate treatment for major depression both before and after attempted suicide. Am J Psychiatry. 1998;155(12):1778-80.

Diagnostic and Statistical Manual of Mental Disorders. 4th ed, Text Revision ed. Washington, DC American Psychiatric Association; 2000.

Teter CJ, Kando JC, Wells BG. Major Depressive Disorder. Basicmedical Key. 2016. DOA:19/10/2016.

Pompili M, Serafini G, Innamorati M, et al. Suicidal Behavior and Alcohol Abuse. International Journal of Environmental Research and Public Health. 2010;7(4):1392-431.

Ferrari AJ, Charlson FJ, Norman RE, Patten SB, Freedman G, Murray CJ, et al. Burden of Depressive Disorders by Country, Sex, Age, and Year: Findings from the Global Burden of Disease Study 2010. PLoS Med. 2013;10(11):e1001547.

Dan LL, Dennis KL, Larry JL, Anthony FS, Stephen HL, Joseph L. Harrison’s Principles of Internal Medicine 19th edition, 17.

Rogers SJ, Cavazos JE. Epilepsy: In pharmacotherapy pathophyl approach Joseph. T. 7 ed, McGraw Hill, New York. 927.

Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry. 2000;157(10):1552-62.

Brigitta B. Pathophysiology of depression and mechanisms of treatment. Dialogues in Clinical Neuroscience. 2002;4(1):7-20.

Steru L, Chermat R, Thierry B, Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl). 1985;85(3):367-70.

Porsolt RD, Bertin A, Jalfre M. Behavioural despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther. 1977;229(2):327-36.

Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Eng l JMed. 2008;358(3):252-60.

Steru L, Chermat R, Thierry B, Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl). 1985;85(3):367-70

Sprouse JS Comparison of the novel antipsychotic ziprasidone with clozapine and olanzapine: inhibition of dorsal raphe cell firing and the role of 5-HT1A receptor activation. Neuropsychopharmacology. 1999;21(5):622-31.

Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STARD report. Am J Psychiatry. 2006;163:1905-17.